<DOC>
	<DOCNO>NCT01964183</DOCNO>
	<brief_summary>To assess effect multiple dos mirabegron postmenopausal adult female subject pharmacokinetics ( PK ) tolterodine metabolite . In addition , safety product assess .</brief_summary>
	<brief_title>Post-marketing Study Evaluate Effect Mirabegron Plasma Concentration Tolterodine</brief_title>
	<detailed_description />
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subjects two year menopause Body weight ( screen ) ≥ 40.0 kg &lt; 70.0 kg Body mass index ( BMI ) ( screen ) ≥ 17.6 kg/m2 &lt; 26.4 kg/m2 Healthy , judge investigator/subinvestigator base medical history result physical examination ( subjective symptom objective finding ) test obtain screen period hospital admission ( single dose phase ) immediately study medication . Received schedule receive investigational drug clinical trial , postmarketing study , clinical study within 120 day screen period screen hospitalization ( Day −2 ) . Donated scheduled donate 400 mL whole blood within 90 day screen period screen hospitalization ( Day −2 ) , 200 mL whole blood within 30 day screen period screen hospitalization ( Day −2 ) , blood component within 14 day screen period screen hospitalization ( Day −2 ) . Any deviation laboratory test screen hospitalization ( Day −2 ) . A deviation normal range blood pressure , pulse rae , body temperature screen hospitalization ( Day 2 ) Supine blood pressure : Systolic blood pressure : ≥90 mmHg , ≤140 mmHg , Diastolic blood pressure : ≥40 mmHg , ≤90 mmHg Supine pulse rate ; ≥40 bpm , ≤99 bpm Axillary body temperature ; ≥35.0°C , ≤37.0°C History drug allergy Upper gastrointestinal disease ( e.g. , nausea , vomit , stomachache ) within 7 day hospitalization ( Day −2 ) Concurrent previous hepatic disease ( e.g. , viral hepatitis , druginduced liver injury , hepatic impairment ) Concurrent previous heart disease ( e.g. , congestive heart failure , angina pectoris , arrhythmia require treatment ) Concurrent previous GI disease ( e.g. , ileus paralytic , gastric atony , intestinal atony , colitis ulcerative , peptic ulcer gastroesophageal reflux esophagitis ; except history appendicitis ) . Concurrent previous renal disease ( e.g. , acute renal failure , glomerulonephritis , interstitial nephritis ) Concurrent previous endocrine disease ( e.g. , hyperthyroidism blood growth hormone abnormal ) Concurrent previous cerebrovascular disorder ( e.g. , cerebral infarction ) Previous use mirabegron tolterodine Excessive smoking drinking habit</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Open-label design</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Mirabegron</keyword>
</DOC>